Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection
Liang Cheng, Haisheng Yu, Guangming Li, Feng Li, Jianping Ma, Jingyun Li, Liqun Chi, Liguo Zhang, Lishan Su
Liang Cheng, Haisheng Yu, Guangming Li, Feng Li, Jianping Ma, Jingyun Li, Liqun Chi, Liguo Zhang, Lishan Su
View: Text | PDF
Research Article AIDS/HIV

Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection

  • Text
  • PDF
Abstract

The direct link between sustained type I interferon (IFN-I) signaling and HIV-1–induced immunopathogenesis during chronic infection remains unclear. Here we report studies using a monoclonal antibody to block IFN-α/β receptor 1 (IFNAR1) signaling during persistent HIV-1 infection in humanized mice (hu-mice). We discovered that, during chronic HIV-1 infection, IFNAR blockade increased viral replication, which was correlated with elevated T cell activation. Thus, IFN-Is suppress HIV-1 replication during the chronic phase but are not essential for HIV-1–induced aberrant immune activation. Surprisingly, IFNAR blockade rescued both total human T cell and HIV-specific T cell numbers despite elevated HIV-1 replication and immune activation. We showed that IFNAR blockade reduced HIV-1–induced apoptosis of CD4+ T cells. Importantly, IFNAR blockade also rescued the function of human T cells, including HIV-1–specific CD8+ and CD4+ T cells. We conclude that during persistent HIV-1 infection, IFN-Is suppress HIV-1 replication, but contribute to depletion and dysfunction of T cells.

Authors

Liang Cheng, Haisheng Yu, Guangming Li, Feng Li, Jianping Ma, Jingyun Li, Liqun Chi, Liguo Zhang, Lishan Su

×

Figure 4

IFNAR1 blockade during persistent HIV-1 infection increases expression of HLA-DR/CD38 and Ki-67 on T cells.

Options: View larger image (or click on image) Download as PowerPoint
IFNAR1 blockade during persistent HIV-1 infection increases expression o...
Humanized mice infected with HIV-1 were treated from 6 to 10 weeks postinfection (wpi) with a mAb against IFN-α/β receptor 1 (IFNAR1) or isotype control (mouse IgG2a) twice per week. Mice were sacrificed at 10 wpi. (A) Summarized data show CD8+ and CD4+ T cells expressing HLA-DR/CD38 (mock, n = 9; HIV-1 + mIgG2a, n = 12; HIV-1 + anti-IFNAR1, n = 12, combined data from 3 independent experiment with mean values ± SEM). (B) Summarized data show CD8+ and CD4+ T cells expressing Ki-67 (mock, n = 6; HIV-1 + mIgG2a, n = 8; HIV-1 + anti-IFNAR1, n = 8, combined data from 2 independent experiments with mean values ± SEM). (C) Correlation analysis between HLA-DR/CD38 expression on T cells and plasma HIV-1 RNA levels. (D) Correlation analysis between Ki-67 expression on T cells and plasma HIV-1 RNA levels. (E) The levels of indicated cytokines in the plasma of humanized mice at 10 wpi. Shown (E) are combined data of 3 independent experiments (mock, n = 6; HIV-1 + mIgG2a, n = 9; HIV-1 + anti-IFNAR1, n = 11) with mean values ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA and Bonferroni’s post hoc test (A, B, and E) and Spearman rank correlation test (C and D).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts